This announcement is a separate document:
百奥泰 自愿披露关于与Hikma Pharmaceuticals USA Inc.就BAT2206（乌司奴单抗）注射液签署授权许可与商业化协议收到里程碑付款的公告
Bio-Thera Solutions voluntarily disclosed the announcement about milestone payment received for the authorization and commercialization agreement signed with Hikma Pharmaceuticals USA Inc. regarding BAT2206 (ustekinumab injection).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.